The Black Vault

This would leave more money for social security for those of us between 20-50 or so. Those that are younger that don't live to be old enough to collect when their time comes,

tigger wrote:New diseases and syndromes, pinnacling pngs, always attack the most vulnerable immune systems first.

6.
2. Post-Marketing Experience
The following additional events have been reported during post-approval use of Fluzone vaccine. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to vaccine exposure.
Blood and Lymphatic System Disorders: Thrombocytopenia, lymphadenopathy
Immune System Disorders: Anaphylaxis, other allergic/hypersensitivity reactions (including urticaria, angioedema)
Nervous System Disorders: GBS, convulsions, myelitis (including encephalomyelitis and transverse myelitis), facial palsy (Bell’s palsy), optic neuritis/neuropathy, brachial neuritis, syncope (shortly after vaccination), dizziness, paresthesia
Page 7 of 19
sanofi pasteur 10 September 2009_v0.3
449/454 Influenza A (H1N1) 2009 Monovalent Vaccine LE5860-5862
Confidential/Proprietary Information
Vascular Disorders: Vasculitis, vasodilation/flushing
Respiratory, Thoracic and Mediastinal Disorders: Dyspnea, pharyngitis, rhinitis
Skin and Subcutaneous Tissue Disorders: Stevens-Johnson syndrome
General Disorders and Administration Site Conditions: Fever, pain, pruritis, asthenia/fatigue, pain in extremities, chest pain
6.
3. Other Adverse Events Associated with Influenza Vaccines
Anaphylaxis has been reported after administration of influenza vaccines. Although Influenza A (H1N1) 2009 Monovalent Vaccine contains only a limited quantity of egg protein, this protein can induce immediate hypersensitivity reactions among persons who have severe egg allergy. Allergic reactions include hives, angioedema, allergic asthma, and systemic anaphylaxis. [See Contraindications (4)]
The 1976 swine influenza vaccine was associated with an increased frequency of Guillain-Barré syndrome (GBS). Evidence for a causal relation of GBS with subsequent vaccines prepared from other influenza viruses is unclear. If influenza vaccine does pose a risk, it is probably slightly more than 1 additional case/1 million persons vaccinated.
Page 8 of 19
sanofi pasteur 10 September 2009_v0.3
449/454 Influenza A (H1N1) 2009 Monovalent Vaccine LE5860-5862
Confidential/Proprietary Information
Neurological disorders temporally associated with influenza vaccination such as encephalopathy, optic neuritis/neuropathy, partial facial paralysis, and brachial plexus neuropathy have been reported.
Microscopic polyangitis (vasculitis) has been reported temporally associated with influenza vaccination.
7.
DRUG INTERACTIONS 8
7.
1. Concomitant Administration with Other Vaccines
There are no data on the concomitant administration of Influenza A (H1N1) 2009 Monovalent Vaccine with seasonal trivalent influenza vaccines.
Influenza A (H1N1) 2009 Monovalent Vaccine should not be mixed with any other vaccine in the same syringe or vial.
If Influenza A (H1N1) 2009 Monovalent Vaccine is to be given at the same time as another injectable vaccine(s), the vaccine(s) should always be administered at different injection sites.
7.
2. Immunosuppressive Therapies
If Influenza A (H1N1) 2009 Monovalent Vaccine is administered to immunosuppressed persons or persons receiving immunosuppressive therapy, immunologic response may be diminished.